Supporting Biotech Development in Madison

As part of our follow up to our recent Biotech in Wisconsin Meetup about professional development skills, we are asking folks to fill out this poll.

Read More

How Could Science #BreaktheInternet?

I saw the Breakthrough Prizes announced this weekend and was excited to learn about the interesting scientists on the list, including Jennifer Doudna who many of us in life science recognize for her CRISPR/Cas9 work. I’ll start out saying that I am glad to see a group of such influential people (Sergey Brin and Anne Wojcicki, Mark […]

Read More

Update from the Swirl (and People are Key to Success)

Last weekend, I uploaded a blog post that included this graphic describing success and said that it really resonated with me. Back in the day, I was the first employee of Quintessence and have been in my fair share of swirls in our efforts to build the company and move our cancer drug forward. One […]

Read More

Innovation: Via a 5th Generation WI Life Science Company

I want to share three themes that struck me from the Dohmen Life Science Services Entrepreneur Summit in Milwaukee this week. Is there an age or stage of company that doesn’t require innovation?  Dohmen started as an apothecary in 1858 and is a private fifth generation company, which has reinvented itself over the last few years. […]

Read More

Could Pharma/Biotech Build an Amazon?

Pharma/Biotech Business Model Innovation When I hear/read about business model innovation in pharma/biotech, the themes generally focus on changes that would improve R&D productivity – moving discoveries from academia to industry more efficiently (some examples of university-related incubators), reproducibility of experiments, venture capital firms creating their own early stage companies, pharma moving R&D innovation external (corporate, biotech and […]

Read More

Experimenting in Academia: Indirect cost disruption?

Yesterday on Twitter I asked the following question and I wanted to follow up because it is an interesting topic. Flip but serious: what is lean startup/incubator/hacker version of a university lab? There is a lot of discussion about funding sources for science/biotechnology as pressure increases on some of the traditional pools of money. Yesterday David Shaywitz shared […]

Read More

US Biosimilars Pathway – A Step Closer to Reality

Today Sandoz announced that their Biologics License Application for filgrastim was accepted by the FDA. This news is significant in part because Zarzio (the brand name for this new product) is the first product to use the 351(k) pathway for biosimilars in the US (rather than the traditional 351(a) BLA). In contrast, there are a […]

Read More

#wearenotwaiting is amazing

This weekend I came across a blog post “CGM in the Cloud: Personal Preferences” written by Kerri, a woman with Type I diabetes. Her post goes through the factors that resulted in her decision to share her continuous glucose monitoring (CGM) data in the cloud. As I went back in the Six Until Me archives, […]

Read More

Biotech: Outside Looking In

In a post in March, I suggested that I would represent the “less glamorous side of things” in the biotech industry. This week gave me an opportunity to attempt that directly. Setting the Stage Earlier this year, Bruce Booth at Atlas Venture started a new thing – a great thing: having management from their biotech portfolio companies […]

Read More

ASCO 2014: People in Drug Development

Reflecting on the American Society of Clinical Oncology annual meeting, I’m left thinking about the importance of people despite the vast amounts of data presented. Cancer drug development is a story whose characters are people, not molecules, not data. The ultimate goal is to help people with cancer (patients) but people are at the center […]

Read More
Follow

Get every new post delivered to your Inbox.

Join 82 other followers